Of note, targeting IL1RAP might be an interesting manner to reduce pro-inflammatory side effect by reducing pro-inflammatory interleukin activation (194), but also by targeting monocytes that are assumed to produce IL-1 and IL-6 in CRS (214, 227). The gene discussed is IL6; the disease is congenital rubella syndrome.